Jodi Wegner, APRN
Women's Health · Lincoln, NENPI 1811982846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Astellas Pharma US Inc at 32.2% of the total. Reporting peaked in 2022 at $441 and has fallen 51.8% since, to $213 in 2025.
Across 88 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$510
- AbbVie$328
- Biohaven Pharmaceutical Holding Company Ltd.$153
- Organon$74
- Pfizer$74
- Bayer$64
- plus $382 from 11 others
What the payments were for
- Food & beverage$1,584100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 18 | $510 |
| AbbVie(2 entities) | 23 | $328 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $153 |
| Organon | 4 | $74 |
| Pfizer | 4 | $74 |
| Bayer | 3 | $64 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Mayne Pharma Commercial LLC | 5 | $45 |
| Agile Therapeutics, Inc. | 3 | $45 |
| Myovant Sciences Inc. | 3 | $39 |
| Avion Pharmaceuticals | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Exeltis, USA Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Merck | 1 | $14 |
How this compares
$1,584 in reported general payments places this provider in the 75th percentile of 60 women's health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 109 | $3,269 |
| DottiEstradiol | 34 | $1,613 |
| Estradiol (Twice Weekly)Estradiol | 16 | $1,486 |
| Levothyroxine Sodium | 24 | $367 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $255 |
| Medroxyprogesterone Acetate | 19 | $207 |
| Trazodone Hcl | 17 | $54 |
Paid to pharmacies, not to this prescriber.
Other women's health in Lincoln
- Allison WhiteLincoln$3K
- Terra VejraskaLincoln$3K
- Jackie OdenLincoln$3K
- Audrey GrayLincoln$2K
- Elizabeth HanselingLincoln$2K
- Lindsey MaasLincoln$1K
- Kathleen HunleyLincoln$1K
- Paula RailsbackLincoln$1K
- Mary SnowLincoln$944
- Emilie LongLincoln$937
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.